Andra AP fonden Buys 38,157 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Andra AP fonden raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 78.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 86,697 shares of the biopharmaceutical company’s stock after purchasing an additional 38,157 shares during the quarter. Andra AP fonden’s holdings in Alnylam Pharmaceuticals were worth $28,685,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ALNY. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $243,000. Geneos Wealth Management Inc. raised its holdings in Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 175 shares during the last quarter. Flow Traders U.S. LLC acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $241,000. Daiwa Securities Group Inc. increased its holdings in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 70,300.0% during the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after acquiring an additional 703 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 1.9%

NASDAQ ALNY opened at $272.67 on Tuesday. The firm has a market cap of $36.40 billion, a PE ratio of 74.50 and a beta of 0.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $266.27 and a 1-year high of $495.55. The stock has a 50-day moving average of $293.92 and a 200-day moving average of $319.69. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.44) EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.26 EPS for the current year.

Analyst Ratings Changes

ALNY has been the topic of several research reports. Bank of America lowered their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Citigroup started coverage on Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They set a “buy” rating and a $380.00 target price for the company. Royal Bank Of Canada lowered their target price on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Truist Financial reduced their price target on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $455.31.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.